BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CardioDx, Inc. 

2500 Faber Place

Palo Alto  California  94303  U.S.A.
Phone: 650-475-2788 Fax: 650-475-2799


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
CardioDx, Inc. And Medison Israel Enter Into An Exclusive Corus® CAD Product Marketing And Sales Agreement 4/9/2014 9:41:33 AM    More...
CardioDx, Inc. Release: Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision-Making In The Assessment Of Patients With Suspected Obstructive Coronary Artery Disease 3/11/2014 10:04:37 AM    More...
CardioDx, Inc. Release: The Corus® CAD Gene Expression Test Can Help Commercial Health Plans Reduce Costs By Improving The Accuracy Of The Diagnostic Workup In Patients With Suspected Obstructive Coronary Artery Disease 2/26/2014 12:58:21 PM    More...
CardioDx, Inc. Release: The Corus(R) CAD Gene Expression Test Significantly Correlates With Plaque Burden And Obstructive Coronary Artery Disease As Validated By CT-Angiography 2/3/2014 10:16:48 AM    More...
CardioDx, Inc. Release: Results From REGISTRY 1 Study Confirm Clinical Utility Of Corus® CAD Genomic Test In Optimizing Care In Elderly Patients Presenting To The Primary Care Clinician With Symptoms Suggestive Of Obstructive Coronary Artery Disease 11/25/2013 7:34:27 AM    More...
CardioDx, Inc. Release: New Data Presented At The American Heart Association Scientific Sessions Highlight The Clinical Utility Of The Corus CAD Gene Expression Test In Women And Demonstrate That The Corus CAD Score Correlates With Cardiovascular Outcomes 11/18/2013 11:11:50 AM    More...
CardioDx, Inc. Nixes IPO, Cites Unfavorable Market Conditions 11/15/2013 10:31:01 AM    More...
CardioDx, Inc. Aims for $92 Million IPO 11/6/2013 7:43:41 AM    More...
CardioDx, Inc.Real-World Registry Study Shows Use of the Corus® CAD Gene Expression Test Helps Reduce Unnecessary Patient Referrals for Cardiac Testing 10/21/2013 10:05:20 AM    More...
CardioDx, Inc. Files for $86.25 Million IPO 10/14/2013 7:22:21 AM    More...
12345